✕
Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
 简体中文
(Simplified Chinese) 繁體中文
(Traditional Chinese)
Life, illuminated.

Advancing fluorescent technology to help improve patient care.

MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function. More >>
To contact us for more information
about the TGFR click here.
For approved transdermal kidney function products see ifu.medibeacon.com for Indication for Use and Important Safety Information about the TGFR including Lumitrace® injection.
Now Approved
Transdermal Kidney Function Technology
Via PMA No. P2300019 for human use
PRECLINICAL
MediBeacon technology is available for preclinical use.
CLINICAL
MediBeacon technologies are progressing through clinical trials.*
MediBeacon is a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement. The science is complex, but the outcomes are simple to understand. How it works >>
Focused on Providing Kidney Insights to Clinicians

The MediBeacon Transdermal GFR System (TGFR) is engineered to allow detection of the change in levels of a fluorescent GFR tracer agent over time via a sensor placed on the patient’s skin. The TGFR Monitor displays this information in the form of a transdermal GFR (tGFR) which may be useful in the understanding of kidney function.

Transdermal GFR Across Skin Tones

The Transdermal GFR System (TGFR) has been designed to report a tGFR across the full range of human skin colors as quantified by the Fitzpatrick Skin Phototype (FSP).

Understanding Renal Function is a Significant Clinical Challenge

According to the CDC 2023 Chronic Kidney Disease (CKD) Factsheet, more than 1 in 7 adults in the US are estimated to have CKD, and approximately 1 in 5 adults with high blood pressure and 1 in 3 adults with diabetes have CKD. The MediBeacon Transdermal GFR System (TGFR) received FDA approval to assess kidney function.

There are no limits to our thinking or what that thinking can accomplish.
Focus areas for
fluorescent agent-
based systems include:
Nephrology

Point of care assessment of renal function
-Learn More

Gastroenterology

Point of care gastrointestinal
permeability measurement
-Learn More

Ophthalmology

Fluorescent agent angiography
-Learn More

Surgery

Fluorescent tracer agent
use in surgery
-Learn More

United States
MediBeacon Inc.
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 269-5808

Germany
MediBeacon GmbH
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15

Greater China
(Commercial Partner)
Huadong Medicine Co., Ltd
Telephone: 4008-269-985
+86-(0)571-89908581
Zip: 310011
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
Email: info@eastchinapharm.com

Science How it Works R&D Platform Product Pipeline Patent Estate Preclinical Clinical Focus Areas Nephrology Gastroenterology Ophthalmology Surgery In Discovery
Publications MediBeacon Publications Preclinical Publications Industry Literature Company History People By the Numbers Quality Commitment News/Media Contact Get Updates Investors General Questions

*MediBeacon products are in various stages of development.

Terms and Conditions | Privacy Policy | © 2025 MediBeacon All Rights Reserved.

COOKIE CONSENT: We use cookies and similar technologies to recognize your repeat visits and preferences, as well as to analyze traffic, among other things. To learn more about cookies, view our Privacy Policy. By clicking “I Accept” on this banner, or using our site, you consent to the use of cookies unless you have disabled them.